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Abstract
Background: Proline-rich tyrosine kinase 2 (Pyk2) is essential in neutrophil degranulation and chemotaxis in vitro.
However, its effect on the process of lung inflammation and edema formation during LPS induced acute lung
injury (ALI) remains unknown. The goal of the present study was to determine the effect of inhibiting Pyk2 on LPS-
induced acute lung inflammation and injury in vivo.
Methods: C57BL6 mice were given either 10 mg/kg LPS or saline intratracheally. Inhibition of Pyk2 was effected by
intraperitoneal administration TAT-Pyk2-CT 1 h before challenge. Bronchoalveolar lavage analysis of cell counts,
lung histology and protein concentration in BAL were analyzed at 18 h after LPS treatment. KC and MIP-2
concentrations in BAL were measured by a mouse cytokine multiplex kit. The static lung compliance was
determined by pressure-volume curve using a computer-controlled small animal ventilator. The extravasated Evans
blue concentration in lung homogenate was determined spectrophotometrically.
Results: Intratracheal instillation of LPS induced significant neutrophil infiltration into the lung interstitium and
alveolar space, which was attenuated by pre-treatment with TAT-Pyk2-CT. TAT-Pyk2-CT pretreatment also
attenuated 1) myeloperoxidase content in lung tissues, 2) vascular leakage as measured by Evans blue dye
extravasation in the lungs and the increase in protein concentration in bronchoalveolar lavage, and 3) the decrease
in lung compliance. In each paradigm, treatment with control protein TAT-GFP had no blocking effect. By contrast,
production of neutrophil chemokines MIP-2 and keratinocyte-derived chemokine in the bronchoalveolar lavage
was not reduced by TAT-Pyk2-CT. Western blot analysis confirmed that tyrosine phosphorylation of Pyk2 in LPS-
challenged lungs was reduced to control levels by TAT-Pyk2-CT pretreatment.
Conclusions: These results suggest that Pyk2 plays an important role in the development of acute lung injury in
mice and that pharmacological inhibition of Pyk2 might provide a potential therapeutic strategy in the
pretreatment for patients at imminent risk of developing acute lung injury.
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Background
Acute lung injury (ALI), which may progress to Acute
Respiratory Distress Syndrome (ARDS), is associated
with high morbidity and mortality in critically ill
patients [1,2]. Despite intense research and multiple
diverse therapeutic trials, there still are few effective
measures for prevention or treatment of ARDS. ARDS
is a frequent complication that emerges in patients hav-
ing sepsis. Lipopolysaccharides (LPS) components of
endotoxin are responsible for the enhanced inflamma-
tory response of ALI and ARDS [3]. The LPS- induced
mouse model of ALI is associated with increased neu-
trophilic lung inflammation and endothelial barrier dys-
function [4-6]. Intranasal instillation of LPS stimulates
airway epithelial cells to release proinflammatory cyto-
kines and chemotactic factors, which causes subsequent
neutrophilic infiltration and ultimately results in lung
tissue injury [7]. This study was designed to determine
whether inhibition of the protein tyrosine kinase Pyk2,
which mediates a wide variety of cellular activities
including cell migration [8], blocks neutrophil infiltra-
tion and lung injury induced by LPS in mice.
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kinase structurally related to focal adhesion kinase (FAK)
[8,9], is a common mediator of signaling by growth fac-
tors, integrins, and G-protein-coupled receptors. Pyk2
inhibition has been shown to decrease neutrophil chemo-
taxis, degranulation, and superoxide release in vitro
[10-12]. Overexpression of dominant negative Pyk2 [11]
or silencing Pyk2 expression [13] reduces chemotaxis of
HL-60-derived neutrophils-like cells. A recent study
demonstrated that Pyk2 is activated by non-muscle myo-
sin light-chain kinase and mediates neutrophil transen-
dothelial migration [14]. Previous in vivo studies have
shown that recruitment of macrophages is attenuated in
Pyk2-deficient mice after stimulation with chemokine
and in response to carageenan [15]. Pyk2-deficient mice
lack marginal zone B cells in the spleen. This has been
associated with a decreased motility of B lymphocytes in
response to a variety of chemokines [16]. Our laboratory
recently has reported that TAT-Pyk2-CT, a fusion pro-
tein in which Pyk2 C-terminal domain (amino acid 680-
1009) is fused to a cell-permeable TAT peptide, blocks
eosinophilic airway inflammation and airway hyperre-
sponsiveness in an ovalbumin- induced mouse model of
asthma [17]. From these observations we have hypothe-
sized that the Pyk2 signaling pathway also may play an
important role in LPS-mediated lung inflammation and
that inhibition of Pyk2 may reduce neutrophil infiltration
in the lung and reduce lung injury in vivo.
The objective of this study was to define the anti-
inflammatory effects of Pyk2 inhibition in a LPS-induced
mouse lung injury model. Intranasal instillation of LPS
into mice can produce a controlled ALI response without
causing systemic inflammation and multi-organ failure
and was therefore chosen for these studies [18]. We
intratracheally administered LPS because this delivery
avoids deposition in the nasal passages [19]. We found
that TAT-Pyk2-CT blocked LPS-induced neutrophilic
lung inflammation and vascular leakage without blocking
MIP-2 and keratinocyte- derived chemokine (KC) pro-
duction in LPS challenged lungs.
Methods
Murine model of ALI
Female C57BL/6 mice, aged 10-12 wk old, were main-
tained on standard laboratory chow ad libitum. Experi-
mental protocols were approved by the University of
Chicago IACUC Review Board. Anesthetized mice were
instilled through a catheter inserted into the trachea with
either saline solution or 10 mg/kg LPS [5] (Strain 055:B5,
Sigma-Aldrich, St. Louis, MO). Animals were studied 18
h after administration of LPS. TAT-Pyk2-CT is a 50 kDa
fusion protein in which the TAT peptide is fused to the
N terminus of the proline-rich C-terminal domain of
Pyk2. TAT-Pyk2-CT acted as a cell membrane permeable
inhibitor of Pyk2 that blocked both Pyk2 binding to its C-
terminal associated proteins (p130
cas, paxillin), as well as
tyrosine phosphorylation of endogenous Pyk2 [12,20].
TAT-GFP is a ~35 kDa fusion protein, which was used
as a control for TAT-Pyk2-CT. The purification of these
TAT fusion proteins has been described previously in
detail [17,20]. TAT-Pyk2-CT at 10 mg/kg was given by
intraperitoneal injection 1 h prior to LPS administration,
and control mice received an equal amount of TAT-GFP
before LPS challenge.
Lung morphology and histology
Mouse lungs were inflated to 25 cm H2O with 1% parafor-
madehyde, embedded in paraffin, stained with hematoxy-
lin-eosin (H&E) and observed by light microscopy. All
lung fields at ×20 magnification were examined for each
sample. Lungs were photographed prior to histological
analysis.
Analysis of BAL fluid
Bronchoalveolar lavage (BAL) was performed by injecting
3× with 0.8 ml of PBS into the lung and gently aspirating
the fluid. The BAL fluid samples were centrifuged to
obtain the cell pellet. Cytoslides were prepared and stained
with Diff-Quick (Dade Diagnostics, Deerfield, IL), and cell
counts were determined using a hemocytometer. Superna-
tants were stored for subsequent analysis of protein and
cytokine contents.
Vascular leakage
To assess vascular leakage, Evans blue dye (30 mg/kg)
was injected into the external jugular vein 2 h before
the termination of the experiment as described [21].
Evans blue dye has a very high binding affinity for
serum albumin. When the vascular barrier in the lung is
compromised, albumin-bound Evans blue moves into
the lung parenchyma. The lungs were perfused free of
blood with phosphate-buffered saline containing 5-mM
ethylenediaminetetraacetic acid via thoracotomy, excised
en bloc, blotted dry, weighed, ands n a pf r o z e ni nl i q u i d
nitrogen. The right lung was homogenized in PBS (1
ml/100 μg tissue), incubated with 2 volumes of forma-
mide to extract the dye (18 h, 60°C), and centrifuged at
5,000 × g for 30 minutes, and the optical density of the
supernatant was determined spectrophotometrically at
620 nm. The extravasated EB concentration in lung
homogenate was calculated against a standard curve and
was expressed as micrograms of Evans blue dye per
gram of lung. The vascular leakage was also determined
by measurement of total protein concentration in super-
natants of BAL using Bradford assay (Bio-Rad, Hercules,
CA).
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Neutrophil parenchymal infiltration, as reflected by
MPO activity, was measured as described [5]. The
mouse lungs were homogenized in 0.8 ml PBS contain-
ing 1% Triton X-100 and centrifuged for 10 min at
10,000 g at 4°C. The supernatants were collected and
MPO activity was measured. Briefly, 50 μls u p e r n a t a n t s
from lung homogenates were added to 100 μlo fs u b -
strate solution (0.01% H2O2, 0.167 mg/mL O-dianizidine
dihydrochloride, and 0.5% hexadecyltrimethylammonium
bromide in 50 mM potassium phosphate buffer, pH 5.5).
The reaction mixture was terminated by addition of 50
μl of sulfuric acid; absorbance was measured at 405 nm
in a microplate reader (Thermomax; Molecular Devices,
Menlo Park, CA).
Measurement of transthoracic static compliance
Transthoracic static compliance was measured in vivo 18
h after saline or LPS challenge. The intubated animal was
connected to a computer-controlled small animal ventila-
tor (Scireq, Vancouver, Canada) that delivered a tidal
volume of 6 ml/kg at a frequency of 120 breaths/min
[22]. Lungs were inflated with 30 cm H2Ot r a n s t h o r a c i c
pressure, and volume was gradually decreased in 0.1-ml
increments. The static lung compliance was determined
by recording the lung pressure change associated with
each volume change in the system when the trachea was
occluded to ambient air. Two full inflation-deflation
cycles were determined for each mouse to achieve a
volume history, and the pressure-volume characteristics
of the lungs were generated.
Measurement of BAL cytokines/chemokines
A mouse cytokine multiplex kit (Mouse Cytokine multi-
plex; Millipore) was used to assay BAL fluid for KC and
MIP-2 according to the manufacturer’s instructions.
Western blot analysis of the tyrosine phosphorylation
of Pyk2
To examine the efficacy of TAT-Pyk2-CT in inhibiting
Pyk2 activation in the lungs, TAT-Pyk2-CT (10 mg/kg)
or TAT-GFP control was administered i.p. 1 h before i.t
administration of LPS. The lungs were excised at 18 h
after LPS challenge, rinsed in PBS, blotted dry, snap fro-
zen in liquid nitrogen, and stored at -80°C. For prepara-
tion of whole-lung cell extracts, 10 mg of ground lung
tissue was resuspended in 500 μl of lysis buffer (10 mM
Tris, pH 7.4, 5 mM MgCl2, 50 U/ml DNase and RNase,
10 μg/ml each of leupeptin, aprotinin and pepstatin,
1 mM PMSF, and then homogenized for 30 s at a speed
of 15,000 rpm in an Ultra-Turrax homogenizer). After a
30-min incubation on ice, homogenates were centri-
fuged at 16,000 g for 10 min. Protein concentrations
were determined using the Bradford assay, the superna-
tants were mixed with Laemmli sample buffer, and
boiled for 5 min. The samples were then used for ana-
lyzing Pyk2 tyrosine phosphorylation.
Samples were subjected to SDS-PAGE, using 7.5% acry-
lamide gels under reducing condition (15 mA/gel). Elec-
trotransfer of proteins from the gels to nitrocellulose
membrane was achieved using a semi-dry system (400
mA, 60 min). The membrane was blocked with 1% BSA
for 60 min, then incubated with 1:1,000 anti-Pyk2 or anti-
Y
402 phospho-Pyk2, diluted in Tris-buffered saline plus
0.05% Tween 20 (TBS-T) overnight. The membranes then
were washed three times for 20 min with TBS-T. Anti-
rabbit IgG conjugated with horseradish peroxidase was
diluted 1:3000 in TBS-T and incubated with nitrocellulose
membrane for 60 min. The membrane was again washed
three times with TBS-T and assayed by an enhanced che-
miluminescence system (Amersham, Arlington Heights,
IL). Western blots were analyzed by Bio-Rad GS-710 den-
sitometer and optical density (OD) data were expressed as
the ratio of phospho-Pyk2 to total Pyk2.
Data analysis
All values were expressed as means ± SEM. When more
than two groups were compared, differences among the
groups were determined by one-way ANOVA followed
by Fisher’s least significant difference test.
Results
Effect of TAT-Pyk2-CT on Pyk2 activation in vivo
LPS challenge caused substantially increased tyrosine
phosphorylation of Pyk2 compared to saline control (Fig-
ure 1). Lungs obtained from TAT-Pyk2-CT-treated and
LPS challenged mice showed significantly reduced
amounts of phosphorylated Pyk2, indicating the inhibition
of Pyk2 activation by TAT-Pyk2-CT. By contrast, levels of
phosphorylated Pyk2 in lungs obtained from LPS chal-
lenged mice pretreated with TAT-GFP control were com-
parable to mice receiving LPS treatment alone. The
normalized optical density of phosphorylated Pyk2 immu-
nostaining in saline controls was 0.25 ± 0.04; this value
increased to 0.71 ± 0.05 after LPS challenge. Phospho-
Pyk2 density remained at the same level in TAT-GFP-
treated mice challenged with LPS and decreased to 0.37 ±
0.02 in mice pretreated with TAT-Pyk2-CT (p < 0.05 vs.
LPS alone).
Effect of Pyk2 inhibition on pathological change in lung
tissues of LPS-induced ALI mice
TAT-Pyk2-CT blocked the characteristic gross anatomic
alterations of acute lung injury caused by LPS (Figure 2A).
Compared to the pink color for the lungs of saline chal-
lenged mice, the lungs of LPS challenged mice were dark
red and swollen, indicating lung inflammation and
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challenged with LPS were similar to those of the saline
control mice, while the lungs of TAT-GFP pretreated
mice challenged with LPS were similar to the lungs of LPS
challenged mice without treatment.
Histological analysis demonstrated that lungs from sal-
ine challenged mice had no morphological evidence of
injury (Figure 2B). The lungs from LPS challenged mice
showed interstitial thickening, alveolar hemorrhage, and
cellular infiltration in both interstitial and alveolar com-
partments, as compared to saline-challenged control
mice. TAT-Pyk2-CT pretreatment decreased all of these
markers of lung injury, while TAT-GFP pretreatment
had no inhibitory effect on lung injury.
Blockade of lung vascular leakage by TAT-Pyk2-CT
LPS induced Evans blue dye accumulation in the lung
parenchyma, which was blocked substantially by TAT-
Pyk2-CT compared to saline challenged controls (Figure
3A). These results further were confirmed by quantita-
tive analysis of Evans blue-labeled albumin extravasation
in the lung preparations (Figure 3B). LPS caused sub-
stantial increase in Evans blue accumulation in the
lungs (34.8 ± 6.2 μg/g vs. 10.9 ± 2.1 μg/g in control ani-
mals; P < 0.05). Treatment with TAT-Pyk2-CT caused
Figure 1 Inhibition of tyrosine phosphorylation of Pyk2 by
TAT-Pyk2-CT in lung tissue. Mice were treated intraperitoneally
with 10 mg/kg TAT-Pyk2-CT or TAT-GFP 1 h prior to LPS challenge.
Mice were sacrificed 18 h after LPS challenge and the lungs were
removed. Lung lysates were analyzed for phosphorylated Pyk2 at
Y402 using Western blot analysis. Upper panel is the representative
immunoblot from three experiments. The lower panel is the relative
optical density of phosphorylated Pyk2 normalized against
corresponding total Pyk2 from three blots. #P < 0.05 vs. saline
control; *P < 0.05 vs. LPS alone group.
Figure 2 Effect of Pyk2 inhibition on lung gross anatomy (A) and histology (B) of LPS-challenged mice.M i c ew e r eg i v e na ni . p .
administration of 10 mg/kg TAT-Pyk2-CT or TAT-GFP 1 h prior to an i.t. administration of LPS. Saline challenged mice were used as negative
control (Con). The lung was photographed and prepared for H&E staining 18 h after saline or LPS challenge. Representative image from one of
six mice per experimental group was shown. Scale bar: 50 μm.
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into lung tissue. Lung vascular permeability was assessed by Evans blue accumulation in the lungs as described in the Materials and Methods.
Results are representative of four independent experiments. 1. Saline control; 2. LPS; 3, TAT-Pyk2-CT + LPS; 4. TAT-GFP + LPS. B. Evans blue
extravasation was quantified by spectrophotometry. Values are means ± SEM; n = 4 per condition. #P < 0.05 vs. control group; *P < 0.05 vs. LPS
alone group. C. Protein concentration was measured in BAL taken from control and LPS-challenged animals. The values presented were the
means ± SEMs (n = 4 for saline control and 6 each for LPS challenged groups). #P < 0.05 vs. control group; *P < 0.05 vs. LPS alone group.
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0.5 μg/g vs. 34.8 ± 6.2 μg/g for LPS alone; P < 0.05).
TAT-GFP pretreatment had no inhibitory effect on
Evans blue dye leakage.
TAT-Pyk2-CT also blocks alveolar protein concentra-
tion (Figure 3C). In mice receiving LPS alone, BAL pro-
tein was increased from 263 ± 33.9 μg/ml for saline
challenged control to 1020 ± 64.0 μg/ml (p < 0.05 vs.
saline control). Pretreatment with TAT-Pyk2-CT
blocked maximal protein concentration in the BAL to
389 ± 53.7 μg/ml (p < 0.05, vs. LPS alone). TAT-GFP
pretreatment had no inhibitory effect.
Effect of Pyk2 inhibition on neutrophilic inflammation
during LPS-mediated ALI in mice
TAT-Pyk2-CT caused substantial inhibition of neutro-
phil infiltration in BAL and lung parenchyma caused by
LPS challenge (Figure 4). The baseline BAL neutrophil
count was 0.09 × 10
4 ± 0.08 for the saline challenged
control, and increased to 92.2 × 10
4 ± 14.7 after LPS
challenge (Figure 4A). Mice receiving TAT-Pyk2-CT 1 h
before LPS challenge reduced neutrophil counts by
~75% (p < 0.05). Control TAT-GFP did not block neu-
trophil infiltration into the alveolar space.
LPS instillation also caused significant increase in lung
MPO activity compared with the control group (Figure 4B).
Lung MPO concentration, expressed as optical density
(OD) per 150 μg/ml protein, increased to 0.31 ± 0.04 arbi-
trary units after LPS administration compared with 0.08 ±
0.02 units for saline-treated control mice (Figure 4B; P <
0.05). Intraperitoneal injection of 10 mg/kg of TAT-Pyk2-
CT 1 h before LPS exposure significantly reduced MPO
activity to 0.18 ± 0.02 units compared with the LPS group,
while treatment with TAT-GFP had no significant effect.
Effect of TAT-Pyk2-CT on proinflammatory cytokines in
the alveolar space
TAT-Pyk2-CT did not block the secretion of chemokines,
macrophage inflammatory protein-2 (MIP-2) and kerati-
nocyte-derived chemokine (KC; also called CXCL1 che-
mokine), two potent known neutrophil-recruiting
chemokines [23]. Both chemokines were increased in BAL
fluid of mice receiving LPS compared with the saline trea-
ted mice (Figure 5A and 5B). LPS induced a 33-fold
increase in KC (9.36 ± 1.01 vs. 0.29 ± 0.14 ng/ml) and
470-fold increase in MIP-2 (4.56 ± 1.28 vs. 0.01 ± 0.001
ng/ml), which was not attenuated by TAT-Pyk2-CT.
Blockade of static lung compliance by TAT-Pyk2-CT
Pretreatment with TAT-Pyk2-CT blocked substantially
the decrease in lung compliance caused by LPS. Adminis-
tration of intratracheal LPS into mice 18 h before mea-
surement caused a right shift of pressure-volume (P-V)
curves (Figure 6A) compared with baseline P-V curves
generated from saline-challenged mice. Pretreatment with
TAT-Pyk2-CT, but not TAT-GFP, significantly blocked
the downward shift in Pressure-Volume curve caused by
LPS.
Data also were analyzed as lung compliance. Composite
change i nt r a n s t h o r a c i cs t a t i cc o m p l i a n c ew a sd e r i v e d
from the linear portion of the P-V curves in each group.
Transthoracic static compliance was measured at 10 cm
H2O (Figure 6B). Static compliance decreased from 0.61 ±
0.06 ml of saline control to 0.46 ± 0.03 ml after LPS treat-
ment (P < 0.05 vs. saline control). This reduction in trans-
thoracic static compliance caused by LPS was attenuated
to 0.61 ± 0.04 ml in LPS-challenged mice pretreated with
TAT-Pyk2-CT (P < 0.05 vs. LPS alone group). Treatment
with TAT-GFP control did not block the reduction in sta-
tic compliance caused by LPS.
Discussion
The objective of this investigation was to examine the
role of Pyk2 in mediating ALI caused by LPS in a
Figure 4 Effect of Pyk2 inhibition on neutrophil infiltration in
alveolar space and lung tissues of LPS-challenged mice. Mice
were given an i.p. administration of TAT-Pyk2-CT (10 mg/kg) 1 h
prior to an i.t. administration of LPS. BALF was collected at 18 h
following LPS challenge to measure the number of neutrophils (A),
and lung tissue homogenates were used to measure MPO activity
(B). Saline challenged animals served as controls (con). Each bar
represented the mean ± SEM of 4 (saline control) or 6 (LPS
challenged groups) mice. #P < 0.05 vs. control group; *P < 0.05 vs.
LPS alone group.
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activation is an important step in the LPS-induction of
ALI. We find that TAT-Pyk2-CT effectively blocked the
LPS-induced 1) inflammatory cell migration into the
lung, 2) protein leakage, and 3) reduction of lung static
compliance caused by LPS.
In ALI, the predominant infiltrating inflammatory cells
are neutrophils, which play an important role in the
pathogenesis in most cases of ALI [24]. When ALI
occurs, neutrophils adhere to the capillary endothelium
and migrate into the air spaces. Activated neutrophils
then release lipid mediators, oxidants, proteases, and
other inflammatory mediators, which results in lung
injury [25]. As expected, mice exposed to LPS exhibited
substantial recruitment of neutrophils into the airways.
Treatment with TAT-Pyk2-CT blocked LPS-induced
increase in the number of neutrophils in the BAL and
lung tissues (Figure 4). Lung histological examination
demonstrates that TAT-Pyk2-CT has a significant anti-
inflammatory activity during LPS-induced ALI (Figure 2).
The infiltration of neutrophils, hemorrhage, and alveolar
edema were found to be common and prominent in the
LPS group but rare in the TAT-Pyk2-CT pretreated
group. These findings may suggest that the protective
effect of TAT-Pyk2-CT on ALI caused by LPS was partly
attributed to an attenuation of neutrophil infiltration into
the lung tissue. The precise extent of neutrophilic effects
vs. other causes of increased vascular leak could not be
assessed in these studies in vivo. However, investigations
in vitro suggest that neutrophils augment vascular leak
through increased interendothelial gap formations
[26,27].
LPS increases lung barrier permeability [28], which
results in alveolar edema and concomitant reduction of
lung compliance [29,30]. To quantify the magnitude of
pulmonary edema, we measured total protein concentra-
tion in the BAL and Evans blue dye extravasation in the
lungs. As expected, LPS instillation was found to cause a
significant increase in BALF protein concentration and
Evans blue dye extravasation into the lungs. LPS-induced
increases in these two parameters were inhibited by TAT-
Pyk2-CT (Figure 3). Increase in lung barrier permeability
Figure 5 Effect of Pyk2 inhibition on production of MIP-2 and
KC in the BALF of LPS-challenged mice. Mice were given an i.p.
administration of 10 mg/kg TAT-Pyk2-CT 1 h prior to an i.t.
administration of LPS. BALF was collected at 18 h following LPS
challenge to analyze the concentration of MIP-2 and KC. The values
presented were the means ± SEM (n = 4 for control, 12 for LPS
alone, 9 for TAT-Pyk2-CT + LPS, and 10 for TAT-GFP + LPS). #P <
0.05 vs. control group; *P < 0.05 vs. LPS alone group.
Figure 6 Effects of TAT-Pyk2-CT on reduced transthoracic static
compliance caused by intratracheal administration of LPS.M i c e
were pretreated with 10 mg/kg TAT-Pyk2-CT or TAT-GFP 1 h before
saline or 10 mg/kg LPS challenge, and (A) pressure-volume (P-V) curves
were generated at 18 h after challenge. B. Decrease in transthoracic
static compliance caused by LPS treatment. Measurements were
means ± SEM at 10 cm H2O for each group (n = 6). #P <0 . 0 5vs.s a l i n e
control group; *P < 0.05 vs. LPS alone group.
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trophil-mediated [4,24]. Previous studies also have shown
that Pyk2 critically regulates the chemotaxis of neutrophils
and differentiated neutrophil-like HL60 cells in vitro
[11,13]. Pyk2-/- neutrophils have reduced migration on
fibrinogen-coated surface and impaired adhesion-depen-
dent release of granular proteins [10]. While these in vitro
observations suggest a potential role for Pyk2 involvement
in neutrophil mediated lung injury, other potential
mechanisms also may be altered by Pyk2 inhibition in
vivo. Pyk2 has been identified recently as a potential tyro-
sine kinase involved in the regulation of VE-cadherin
phosphorylation and endothelial junctional integrity
[31,32]. Therefore, while the in vivo therapeutic effect of
Pyk2 inhibition is demonstrated in these experimental
results, the attribution of a single mechanism (i.e. neutro-
phil mediated endothelial damage) may be insufficient to
explain all aspects of vascular leak in LPS-induced ALI.
Proinflammatory cytokines appear in the early phase of
an inflammatory response, playing a critical role in ALI
development, and contribute to the severity of lung injury
[33]. In the present study, we found that LPS induces the
production of large amounts of MIP-2 and KC detected in
the BAL of LPS treated mice. However, Pyk2 inhibition by
TAT-Pyk2-CT did not block the production of KC and
MIP-2 in BAL (Figure 5). In fact, KC concentration was
increased in BAL of TAT-Pyk2-CT treated and LPS chal-
lenged mice. This may be explained by the negative feed-
back mechanism since TAT-Pyk2-CT treated and LPS
challenged mice has less neutrophils in the lung. Anand
AR et al. found that inhibition of Pyk2 activity in endothe-
lial cells in vitro by transfection with the catalytically inac-
tive C-terminal Pyk2 significantly blocked LPS-induced
IL-8 production [34]. The inability of Pyk2 inhibition to
affect IL-8 homolog secretion in mouse BAL in our study
may suggest that lung resident cells (such as airway epithe-
lial cells and alveolar macrophages) other than endothelial
cells may be at least in part responsible for the secretion
of IL-8 homologs found in the BAL. Thus, even in the pre-
sence of increased concentrations of chemoattractants in
the alveolar space, inhibition of Pyk2 prevented the LPS-
induced infiltration of neutrophils into the lung. Similar
results have also been observed in mice pretreated with
either a p38 inhibitor [35] or JNK inhibitor [36]. Our
group and others have reported that Pyk2 inhibition atte-
nuated chemotaxis of neutrophils and HL60 derived neu-
trophil-like cells to various chemokines [11,13]. Pyk2
inhibition blocked the formation of stable lamellipodia in
adherent eosinophils [12,20], which is necessary for subse-
quent cell migration.
Previous studies have shown that LPS-induced ALI
and mortality can be attenuated by pretreating animals
with tyrosine kinase inhibitors, although the precise
kinase through which these inhibitors exert their effects
is not entirely clear [37,38]. Other studies have demon-
strated that mice deficient in Src kinase members (hck
and fgr double knockouts) are resistant to endotoxin-
mediated injury and have reduced neutrophil migration
into tissues. These same studies noted that this phe-
nomenon occurred without an effect on serum cytokine
levels [39]. A recent study found that the Src family
kinase inhibitor PP1 inhibited the LPS-induced increase
in neutrophil recruitment and protein leakage [40]. Src
family kinases have been implicated in causing maximal
Pyk2 activation [41], and were recently found to cause
Pyk2 autophosphorylation in T cells [42]. Therefore, it
may be reasonable to speculate that these tyrosine
kinase inhibitors and Src family kinase inhibitors exert a
beneficial anti-inflammatory effect by preventing the full
activation of Pyk2.
It is important to note discrepancy between previous
reports using mouse neutrophils isolated from bone mar-
row of Pyk2 knockout mice and human blood neutro-
phils treated with TAT-Pyk2-CT. Using neutrophils
isolated from bone marrow of Pyk2 knockout mice,
Kamen et al. found that Pyk2 was required for integrin-
mediated degranulation and migration but was not
involved in adhesion-induced cell spreading or activation
of superoxide production [10]. Using TAT-Pyk2-CT as a
Pyk2 inhibitor for human neutrophils, Han et al. sug-
gested that Pyk2 was required for TNF-mediated super-
oxide release and neutrophil spreading [12]. By contrast,
TAT-Pyk2-CT did not affect degranulation of adherent
neutrophils or alter neutrophil killing of bacteria. These
results, obtained with human neutrophils, obviously dif-
fer significantly from observations with Pyk2-deficient
murine bone marrow neutrophils. In the current study,
we found that neutrophil migration into the lung is
blocked by TAT-Pyk2-CT, which also is different from
Pyk2
-/- mice, showing no defect of neutrophil infiltration
to skin pouch in response to subcutaneious SA u r e u s
[10]. By contrast, Xu et al. found that mouse neutrophils
deficient of non-muscle myosin light chain kinase, which
is required for the recruitment and activation of Pyk2,
had impaired ability to infiltrate to the lung ex vivo in
response to LPS or fMLP [14]. There are many potential
explanations for these disparate observations, such as
potential compensation for Pyk2 deficiency by overex-
pression of other kinases, differences in experimental
approaches, differences especially between cells from dif-
ferent species, i.e. mature human blood cells and murine
bone marrow cells. Likewise, differences in stimulus (S.
Aureus vs. LPS) and inflammation loci (skin pouch vs.
lung) could also account for disparate outcomes. It has
been found that neutrophil infiltration into loci of inflam-
mation is tissue-specific and regulated by different signal-
ing mechanisms [41]. Lastly, off-target effects of TAT-
Pyk2-CT could not be excluded.
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Page 8 of 10In summary, we demonstrate that Pyk2 may play a
critical role in the pathogenesis of LPS-induced lung
injury, and that TAT-Pyk2-CT used as a Pyk2 inhibitor
has a protective effect on LPS-induced ALI. Pretreat-
ment with TAT-Pyk2-CT results in a significant reduc-
tion in both lung neutrophilia and protein leakage in
the BALF. Histological examination also shows that
TAT-Pyk2-CT has a significant anti-inflammatory activ-
ity during LPS-induced ALI. Since effective anti-inflam-
matory pharmacotherapy for ALI is still not available,
Pyk2 inhibition may represent a potential preventive
intervention point in the treatment of ALI.
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